Alnylam Pharmaceuticals appoints Phil Davey as Country Manager, UK & Ireland

Alnylam Pharmaceuticals appoints Phil Davey as Country Manager, UK & Ireland

MAIDENHEAD, UK, 23 May 2022 - Alnylam Pharmaceuticals has announced the appointment of Phil Davey as Country Manager of the UK and Ireland.

Commenting on his appointment, Phil said: "I am delighted to have joined Alnylam as Country Manager for the UK and Ireland. Alnylam is delivering on its mission to translate RNA interference (RNAi) technology into a new class of innovative therapeutics offering much-needed treatment options to patients living with rare diseases and the potential to transform their outcomes. I'm excited to work with this strong team to continue to deliver on this commitment to patients, driving the growth of our current UK portfolio as well as a first-in-class pipeline of new medicines for patients living with both rare and more common diseases across the UK and Ireland. "

Phil Davey is an experienced and agile leader, with over 18 years of experience in senior roles within the biotechnology and pharmaceutical industry, during which he has worked in both regional and local roles in both the US and UK. He joins Alnylam from Alexion Pharmaceuticals, where he spent the last seven years, most recently as Vice President, Business Unit Lead, leading the company's Coagulation business.

Phil takes on the role of Country Manager from Brendan Martin who has served in this role since 2016, and who has assumed a newly-created global role within Alnylam as Senior Vice President, Commercial Innovation Lead.

"As Alnylam’s largest site outside the United States, our UK and Ireland business hub brings together a diverse range of highly-skilled expertise areas, including commercial, medical affairs, regulatory, and clinical operations and as such, it plays a vital role in our company's global and international operations, " said Kasha Witkos, Senior Vice President, Head, International Region at Alnylam. "We are honoured to welcome Phil to Alnylam and are confident that his dynamic leadership, vision and exceptional track record in creating change for patients will bring significant value to our business and help build our company’s reputation and leadership in RNAi. I look forward to seeing our UK and Ireland business and team continue to grow, develop and prosper under Phil's leadership. "

Alnylam was founded in 2002 in Cambridge, Massachusetts, where its global headquarters is based. Alnylam's international region is headquartered in Zug, Switzerland and the company has critical regional hubs in Maidenhead, UK and Amsterdam, The Netherlands. Alnylam has further office locations across the international region, including the UK, Netherlands, Switzerland, Germany, France, Spain, Italy, Portugal, Belgium, Sweden and Japan. The UK & Ireland site is located in Maidenhead, Berkshire and has more than 100 employees who work across a range of expertise areas, including commercial, medical affairs, regulatory, clinical operations, HR, corporate communications, business operations and procurement.